Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 5/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 5/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 10/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3590196 | 0.90 | RXRA (0.52) | RXRANR1H2NR1H3HSD11B1PTGS2 | |
| SCHEMBL3586606 | 0.88 | TRPA1 (0.39) | RXRANR1H2NR1H3HSD11B1TRPA1 | |
| SCHEMBL3587049 | 0.80 | PTGS2 (0.44) | RXRANR1H2NR1H3HSD11B1TRPA1 | |
| SCHEMBL3576966 | 0.80 | PTGS2 (0.41) | RXRANR1H2NR1H3HSD11B1TRPA1 | |
| SCHEMBL3571793 | 0.79 | PTGS2 (0.55) | RXRANR1H2NR1H3PTGS2PTGS1 | |
| SCHEMBL3580753 | 0.77 | HSD11B1 (0.49) | RXRANR1H2NR1H3HSD11B1PTGS2 | |
| SCHEMBL3573079 | 0.77 | HSD11B1 (0.42) | RXRANR1H2NR1H3HSD11B1 | |
| SCHEMBL3579767 | 0.77 | RXRA (0.46) | RXRANR1H2NR1H3HSD11B1PTGS2 | |
| SCHEMBL15988532 | 0.77 | RXRA (0.54) | RXRANR1H2NR1H3PTGS2PTGS1 | |
| SCHEMBL3588699 | 0.76 | RXRA (0.59) | RXRANR1H2NR1H3HSD11B1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569352-B2 | Imidazole based LXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2013-10-29 | — | — | US | disclosed |
| US-20100075964-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075964-A1 | IMIDAZOLE BASED LXR MODULATORS | NR1H2, NR1H3, NR1I2 | RXRA 17/4885NR1H2 1/4885NR1H3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.